Researchers combine dichloroacetate and metformin with a 10-fold lower Navitoclax dose, selectively clearing senescent cells while limiting platelet toxicity and advancing clinical senolytic use. A ne...
The 2026 Alzheimer’s clinical trials pipeline shows a strategic shift from amyloid to inflammation and tau targets, with combination therapies and repurposed drugs leading the way. In 2026, the Alzh...
Alzheimer’s Drug Development Revolution: Inflammation and Tau Take Center Stage as Amyloid Era Fades
The 2024 pipeline report reveals a dramatic shift from amyloid to inflammation and tau targets, with repurposed drugs and combination therapies leading a new era of Alzheimer’s treatment. New re...